Oseltamivir Pediatric Dose — Influenza Treatment
Oseltamivir is a neuraminidase inhibitor antiviral that reduces influenza A and B viral replication by blocking viral release from infected cells. It is the primary oral antiviral agent used in pediatrics for the treatment and prophylaxis of influenza. Early initiation — ideally within 48 hours of symptom onset — is associated with the greatest clinical benefit.
Pediatric Dosing
Dosing is stratified by age and weight. All regimens are administered orally every 12 hours for 5 days. Note: Infectious Disease (ID) consultation is required for patients younger than 6 months of age.
| Age / Weight | Dose (every 12 hrs × 5 days) |
|---|---|
| Younger than 3 months | 12 mg PO q12h |
| 3–5 months | 20 mg PO q12h |
| 6–11 months | 25 mg PO q12h |
| >12 months and <15 kg | 30 mg PO q12h |
| 15–23 kg | 45 mg PO q12h |
| 23–40 kg | 60 mg PO q12h |
| >40 kg | 75 mg PO q12h |
Available oral solution concentrations: 6 mg/mL and 12 mg/mL. Verify the concentration on hand before calculating volume. For example, a 20 kg child (dose: 45 mg) using the 6 mg/mL solution would receive 7.5 mL per dose; using the 12 mg/mL solution, 3.75 mL per dose.
Indications and Clinical Context
Oseltamivir is indicated for the treatment of acute uncomplicated and complicated influenza in pediatric patients of all ages when influenza virus is circulating in the community. Per AAP and CDC guidance, treatment is particularly recommended for hospitalized patients, children with severe or progressive illness, and those at high risk for complications — including infants younger than 2 years, immunocompromised patients, and children with chronic pulmonary, cardiac, or neurologic conditions. Antiviral benefit is greatest when therapy is initiated within 48 hours of symptom onset, though treatment may still be considered in high-risk or hospitalized patients presenting later.
For patients younger than 6 months of age, limited pharmacokinetic and safety data exist; ID consultation is required prior to initiation in this age group to guide dosing and risk-benefit assessment.
Administration and Monitoring
Oseltamivir is administered orally as capsules or suspension. When using the oral suspension, confirm the concentration dispensed (6 mg/mL or 12 mg/mL) to avoid dosing errors. The suspension may be taken with food to reduce gastrointestinal upset. If the commercial suspension is unavailable, an extemporaneous preparation from capsules may be compounded; consult institutional pharmacy protocol for appropriate concentration and stability data.
- Route: Oral only (PO)
- Duration: 5-day course for treatment
- Common adverse effects: Nausea, vomiting (most common; mitigated by administration with food), and occasional headache
- Renal dosing: Dose adjustment may be required in renal impairment; consult institutional protocol
- ID consult: Mandatory for patients younger than 6 months of age
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.